Immunotherapy and Targeted in Melanoma

Sanjiv S. Agarwala, MD Professor, Temple University School of MediCine CMO, Cancer Expert Now




- Immunotherapy
- Targeted therapy
- Choosing between immunotherapy & targeted therapy as first-line
- Combining immunotherapy with targeted therapy
- Future directions



- Immunotherapy
- Targeted therapy
- Choosing between immunotherapy & targeted therapy as first-line
- Combining immunotherapy with targeted therapy
- Future directions

Anti-CTLA4 Ipilimumab Changed the Landscape




HR: 0.66 and 0.68 Pre-treated pts Ipi 3 mg/kg +/- gp100

Hodi FS, et al. N Engl J Med. 2010;363:711-23.

HR: 0.72 First line Ipi 10 mg/kg + DTIC

Robert C, et al. N Engl J Med. 2011;364:2517-26.

Long-Term Data with Single Agent Ipilimumab in Melanoma



1. Schadendorf et al. J Clin Oncol 2015;33:1889-1894; 2. Current analysis; 3. Poster presentation by Dr. Victoria Atkinson at SMR 2015 International Congress.

Ipilimumab became the standard of care for advanced melanoma in 2011

But can we do better?

Keynote-006 Front-line Pembrolizumab vs Ipilimumab


Patients

- Unresectable, stage III or IV melanoma
- ≤1 prior therapy, excluding anti–CTLA-4, PD-1, or PD-L1 agents
- Known BRAF status^b
- ECOG PS 0-1
- No active brain metastases
- No serious autoimmune disease

Stratification factors:

- ECOG PS (0 vs 1)
- Line of therapy (first vs second)
- PD-L1 status (positive^c vs negative)

^aPatients enrolled from 83 sites in 16 countries.



- Primary end points: PFS and OS
- Secondary end points: ORR, duration of response, safety

^bPrior anti-BRAF targeted therapy was not required for patients with normal LDH levels and no clinically significant tumor-related symptoms or evidence of rapidly progressing disease.

^cDefined as membranous PD-L1 expression in ≥1% of tumor cells as assessed by IHC using the 22C3 antibody.


Long-Term Survival From Pembrolizumab Completion and Pembrolizumab Retreatment: Phase 3 KEYNOTE-006 in Advanced Melanoma

G. V. Long¹⁻⁴, J. Schachter⁵, A. Arance⁶, J.-J. Grob⁷, L. Mortier⁸, A. Daud⁹, M. S. Carlino^{1,2,10,11}, A. Ribas¹²,
C. M. McNeil^{2,13}, M. Lotem¹⁴, J. Larkin¹⁵, P. Lorigan¹⁶, B. Neyns¹⁷, C. U. Blank¹⁸, T. M. Petrella¹⁹, O. Hamid²⁰,
E. Jensen²¹, C. Krepler²¹, S. J. Diede²¹, C. Robert²²


ASCO 2020

¹Melanoma Institute Australia, Sydney, NSW, Australia; ²University of Sydney, Sydney, NSW, Australia; ³Royal North Shore Hospital, Sydney, NSW, Australia; ⁴Mater Hospital, North Sydney, NSW, Australia; ³Cheba Medical Center, Tel HaShomer Hospital, Tel Aviv, Israel, ⁴Hospital Clinic de Barcelona, Barcelona, Spain; ⁷Aik Marseille University, Höpital de la Timone, Marseille, France; ¹Université Lille, Centre Hospital, Felder, Regional Universitaire de Lille, Lille, France; ¹UCISF, San Francisco, CA, USA; ¹³Blacktown Hospital, Blacktown, NSW, Australia; ¹¹Crown Princess Mary Cancer Centre, Westmead Hospital, Sydney, NSW, Australia; ¹¹Corwn Princess Mary Cancer Centre, Westmead Hospital, Sydney, NSW, Australia; ¹¹Corwn Princess Mary Cancer Centre, Westmead Hospital, Sydney, NSW, Australia; ¹¹Corwn Princess Mary Cancer Centre, Westmead Hospital, Sydney, NSW, Australia; ¹¹Corwn Princess Mary Cancer Centre, Westmead Hospital, Sydney, NSW, Australia; ¹¹Corwn Princess Mary Cancer Centre, Westmead Hospital, Sydney, NSW, Australia; ¹¹Corwn Princess Mary Cancer Centre, Westmead Hospital, Sydney, NSW, Australia; ¹¹Corwn Princess Mary Cancer Centre, Westmead Hospital, Sydney, NSW, Australia; ¹¹Corwn Princess Mary Cancer Centre, Westmead Hospital, Sydney, NSW, Australia; ¹¹Corwn Princess Mary Cancer Centre, Westmead Hospital, Sydney, NSW, Australia; ¹¹Sharett Institute of Concology, Hadassah Hebrew Medical Center, Jerusalem, Israel; ¹¹Royal Marsden Hospital, London, England; ¹¹University of Manchester and the Christie NHS Foundation Trust, Manchester, England; ¹¹Universitair Ziekenhuis Brussel, Brussel, Brussel, Belgium; ¹¹Netherlands Cancer Institute, Amsterdam, Netherlands; ¹¹Sunnybrook Health Sciences Centre, Toronto, ON, Canada; ²⁰The Angeles Clinic and Research Institute, Los Angeles, CA, USA; ²¹Merck & Co., Inc., Kenilworth, NJ, USA; ²²Coutave Roussy and Paris-Sud University, Villejutif, France

Overall Survival: Total Population




Data cut-off. July 31, 2019. "Based on Cox regression model with treatment as a covariate stratified by line of therapy (fst vs 2nd), PD-11 status (positive vs negative) and ECOG (0 vs 1); in instances where there were no patients in one of the treatment groups involved in a comparison for a particular stratum, that stratum was excluded from the treatment comparison.



- Two pembrolizumab arms pooled as similar efficacy²
- Patients completing ≥94 weeks of pembrolizumab with SD/PR/CR were considered to have completed 2 years of treatment
- Patients could receive a 2nd course of 1 year of pembrolizumab if progressed after SD/PR/CR
- Data cut-off: July 31, 2019; median follow-up: 66.8 months (range, 65.0-70.4); time from last patient enrolled to data cutoff, 65.0 months

^aPrior anti-BRAF therapy was not required for patients with normal LDH levels and no clinically significant tumor-related symptoms or evidence of rapidly progressing disease. ^bDefined as ≥1% staining in tumor and adjacent immune cells as assessed by IHC using 22C3 antibody.

Overall Survival: First Line Patients




Data cut-off: July 31, 2019. "Based on Cox regression model with treatment as a covariate stratified by line of threatmay (1st vs 2nd), PD-L1 status (positive vs negative) and ECOG (0 vs 1); in instances where there were no patients in one of the treatment groups instrained for a particular stratum, that stratum vas excluded from the treatment comparison.

Anti PD-1 is better than ipilimumab frontline and responses are durable even after stopping treatment

But what about combining CTLA-4 and PD-1?


CheckMate 067: study design



Database lock: October 19, 2020; minimum follow-up of 77 months for all patients

"The study was not powered for a comparison between NIVO-IPI and NIVO. "NIVO - IPI or NIVO vs IPI alone. "NIVO - IPI vs NIVO alone. AJCC, American Joint Committee on Cancer; - III stage, metastanic stage; OIRR, objective response rate; PO-L1, programmed death ligand 1; PFS, progression-free survival; QZW, every 2 weeks; QZW, every 3 weeks.


Progression-free survival




Descriptive analysis.

5

Overall survival




Combination or monotherapy?



Decision Factors

- Efficacy
- Toxicity

PFS by best overall response, 12-month landmark analysis^a



Patients with a best overall response of a CR, PR, or SD at 12 months were followed for PFS^b

"To address guarantee time bias, landmark analysis excluded patients who hait an event during the first 12 months. Since PD to a PPS event, patients with a best overall response of PD were excluded from this analysis.

Decision Factors

- Efficacy
- Toxicity

Safety Summary


• With an additional 19 months of follow-up, safety was consistent with the initial report¹

	NIVO+IPI (N=313)		NIVO (N=313)		IPI (N=311)	
Patients reporting event, %	Any Grade	Grade 3-4	Any Grade	Grade 3-4	Any Grade	Grade 3-4
Treatment-related adverse event (AE)	95.8	58.5	86.3	20.8	86.2	27.7
Treatment-related AE leading to discontinuation	39.6	31.0	11.5	7.7	16.1	14.1
Treatment-related death, n (%)	2 (0.6)ª		1 (0.3) ^b		1 (0.3) ^b	

- Most select AEs were managed and resolved within 3-4 weeks (85–100% across organ categories)
- ORR was 70.7% for pts who discontinued NIVO+IPI due to AEs, with median OS not reached

^aCardiomyopathy (NIVO+IPI, n=1); Liver necrosis (NIVO+IPI, n=1). Both deaths occurred >100 days after the last treatment. ^bNeutropenia (NIVO, n=1); colon perforation (IPI, n=1).¹


Checkmate 067: Safety Onset Grade 3–4 Treatment-Related Select AEs



Circles represent medians; bars signify ranges

Larkin J et al ECC 2015

Treatment-free interval following study therapy discontinuation




Median duration of treatment was 3.6 mo (range, 0-80.1) with NIVO + IPI, 8.6 mo (0-79.8) with NIVO, and 3.7 mo (0-49.9) with IPI

Combination immunotherapy ipilimumab + nivolumab has become the preferred treatment option (if you select immunotherapy)




- Immunotherapy
- Targeted therapy
- Choosing between immunotherapy & targeted therapy as first-line
- Combining immunotherapy with targeted therapy
- Future directions


Targeted Therapy: MAPK Pathway



BRAF Mutation




Dual BRAF and MEK Inhibition Is Associated With High Response Rates and Improved PFS and OS





- Immunotherapy
- Targeted therapy
- Choosing between immunotherapy & targeted therapy as first-line
- Combining immunotherapy with targeted therapy
- Future directions


Melanoma Therapy Decision Point



OS by BRAF mutation status^a

BRAF mutant

BRAF wild-type




Key Ongoing Trials Evaluating Targeted Therapy Vs Combination Immunotherapy

	SECOMBIT	EORTC-1612-MG	DREAMseq
Population	Stage III (unresectable) or IV	stage III or IV (cutaneous or mucosal)	Stage III (unresectable) or IV
	BRAF V600-mutant	BRAF V600E or V600K-mutant	BRAF V600-mutant
N	251	270	300
Primary Endpoint	OS	PFS	OS
Primary Completion	April 2021	April 2022	October 2022
IO Regimen	NIVO 1 mg/kg IV + IPI 3 mg/kg IV Q3W x 4 → NIVO 3 mg/kg IV Q2W	NIVO 3 mg/kg Q3W + IPI 1 mg/kg Q3W x4 \rightarrow NIVO 480 mg Q4W	NIVO 1 mg/kg + IPI 3 mg/kg or NIVO 3 mg/kg + IPI 1 mg/kg → NIVO 3 mg/kg maintenance
Targeted Regimen	Encorafenib 450 mg PO QD + Binimetinib 45 mg PO BID	Encorafenib 450 mg QD + Binimetinib 45 mg BID	Dabrafenib 150 mg PO BID + Trametinib 2 mg PO QD
Sequencing	Targeted \rightarrow IO IO \rightarrow Targeted Targeted \rightarrow IO \rightarrow Targeted	Targeted → IO IO only	Targeted \rightarrow IO IO \rightarrow Targeted

BID = twice daily; IO = immunotherapy; IPI = ipilimumab; IV = intravenous; NIVO = nivolumab; OS = overall survival; PD = progressive disease; PFS = progression-free survival; PO = orally; Q2W = every 2 weeks; Q3W = every 3 weeks; Q4W = every 4 weeks; QD = once daily.

Clinical trial information: https://clinicaltrials.gov/ct2/show/NCT02631447; https://clinicaltrials.gov/ct2/show/NCT03235245; https://clinicaltrials.gov/ct2/show/NCT02224781


DREAMseq Trial Treatment Schema



*Nivo/Ipi Induction = 12 wks; nivo maintenance = 72 wks


Michael B. Atkins, MD

Progression Free Survival (PFS): Step1 (n=214)



Michael B. Atkins, MD

Overall Survival (OS): Step 1 +/- Step 2




(# at risk)



- Immunotherapy
- Targeted therapy
- Choosing between immunotherapy & targeted therapy as first-line
- Combining immunotherapy with targeted therapy
- Future directions

Antitumoral response: Targeted therapies vs. Immunotherapies (CTLA-4 antibodies)



Presented By Axel Hauschild at 2014 ASCO Annual Meeting




Figure modified from Ribas A et al. Clin Cancer Res. 2012, and Hamid O et al. SMR 2015.

Evaluation of Atezolizumab, Cobimetinib, and Vemurafenib in Previously Untreated Patients With *BRAF*^{V600} Mutation–Positive Advanced Melanoma: Primary Results From the Phase 3 IMspire150 Trial


Grant A. McArthur, M.B., B.S., Ph.D.,¹ Daniil Stroyakovskiy, M.D.,² Helen Gogas, M.D., Ph.D.,³ Caroline Robert, M.D., Ph.D.,⁴ Karl Lewis, M.D.,⁵ Svetlana Protsenko, M.D.,⁶ Rodrigo Pereira, M.D.,⁷ Thomas Eigentler, M.D.,⁸ Piotr Rutkowski, M.D., Ph.D.,⁹ Lev Demidov, M.D.,¹⁰ Georgy Moiseevich Manikhas, M.D.,¹¹ Yibing Yan,¹² Kuan-Chieh Huang, Ph.D.,¹² Anne Uyei, M.D.,¹² Virginia McNally, Ph.D.,¹³ Ralf Gutzmer, M.D.,¹⁴ Paolo Ascierto, M.D.¹⁵

AACR Annual Meeting 2020


Melanoma and Skin Service and Cancer Therapeutics Program, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia; ³Moscow City Oncology Hospital #62 of Moscow Healthcare Department, Moscow, Russia; ³Tist Department of Medicine, Laiko General Hospital, National and Kapodistina University of Athens, Greece, ³Gustave Roussy and Université Paris-Saclay, Villejuif-Paris, France; ⁴University of Colorado Comprehensive Cancer Center, Aurora, CO, USA; ⁴Department of Chemotherapy and Innovative Technologies, N. N. Petrov National Medical Research Center of Anochy, St. Petersburg, Russia; ³Hospital das Clinicas, Porto Alegre, Brazil; ⁴University Hospital Tübingen, Cermany; ³Department of Soft Tissue/Bones Sarcoma and Melanoma, Maria Skidovskez-Curie National Research Institute of Choclogy, Warsaw, Poland; ⁴N. N. Biokhini Russian Cancer Research Center, Ministry of Health, Moscow, Russia; ¹St. Petersburg Oncology Hospital, St. Petersburg, Russia; ¹Genentech, Inc., South San Francisco, CA, USA; ¹Roche Products Ltd, Welwyn, Garden City, UK; ¹Haut-Tumour-Zentrum Hamover (HTZH), Klinik für Dermatologie, ¹Raspital; Melcology Marsaw, Puerlovi, Ban, Klarishin, Karshina, Shadovskez, Chenet, Ministry of Health, Moscow, Russia; ¹St. Petersburg, Russia; ¹Cenentech, Inc., South San Francisco, CA, USA; ¹Roche Products Ltd, Welwyn, Garden City, UK; ¹Haut-Tumour-Zentrum Hamover (HTZH), Klinik für Dermatologie, ¹Rasaw, Pales, Italy.

AACR Annual Meeting 2020

IMspire150: Primary Endpoint: Investigator-Assessed PFS




Common Treatment-Related AEs (≥15%, any grade)



AE, adverse event; ALT, alanine aminotransferase; AST, aspartate aminotransferase; CPK, creatine phosphokinase. Listed AEs were reported at a frequency of ≥15%, along with corresponding frequencies for grade 3/4 events.

IMspire150: Overall Survival




Updated Survival In Patients With BRAF-mutant Melanoma Administered Pembrolizumab, Dabrafenib And Trametinib


Pier Francesco Ferrucci^{1a}; Paolo A. Ascierto^{2a}; Michele Maio³; Michele Del Vecchio⁴; Victoria Atkinson⁵; Henrik Schmidt⁶; Jacob E. Schachter⁷; Paola Queirolo⁸; Georgina V. Long⁹; Rosalie Stephens¹⁰; Inge Marie Svane¹¹; Michal Lotem¹²; Mahmoud Abu-Amna¹³; Eduard Gasal¹⁴; Razi Ghori¹⁵; Scott J. Diede¹⁵; Elizabeth Croydon¹⁵; Antoni Ribas¹⁶

^aBoth authors contributed equally

¹Istituto Europeo di Oncologia IRCCS, Milan, Italy, ²Istituto Nazionale Tumori IRCCS Fondazione 'G. Pascale, ¹Angles, Italy, ²Center for Immuno-Oncology, University Hospital of Siena, Siena, Italy, ⁴Fondazione IRCCS Istituto Autorinale dei Tumori Main, Italy, ²Calialipoli Medica Insearch Fondazione, Greenslopes Private Hospital, Irishane, CDA, sustainel, ⁴Annus University Hospital, Arahus, Denmark, ⁷Ella Lemelbaum Institute for Immuno-Oncology, The Chaim Sheba Medical Center at Tel HaShomer, Cancer Center (Oncology Institute), Ramat Gan, Israel, ⁴BCD, European Institute of Oncology IRCCS, Milan, Italy, ⁴Mainaman Institute Australia, the University of Sydney, Mater and Royal North Shore Hospital, Sydney, ISW, Australia, ⁵Mauckiand City Hospital, Auckland, New Zealand; ¹Merkev Hospital, University of Copenhagen, Herkev, Demmark, ¹³Sharett Institute of Oncology, Hadasah Hebrew Medical Center, Jerusalem, Israel, ¹⁴RD, and Marker, ¹⁴CL, and Chaiman, Hair ¹⁴Clarander, Nul Ski, ¹⁴Merkek & Co., Inc., Kenhwircht, Nu, USA: ¹⁴WICLA and the Jonsson Comorehensive Cancer Center, Conserve Consel to Angeles, CA. USA 1987.



Progression-Free Survival



Ascierto et al. Nature Med 2019

- Deserve on requirement essentiate of PF>, per Investigator assessment. + Based on Cox regression model with treatment as a covariate stratified by ECOG PS (0 vs 1) and LDH (LDH >1.1 × ULN vs =1.1 × ULN); owing to the small number of patients enrolled in the ECOG PS 1 and LDH 31.1 × ULN strata, these strata were combined. Data cutoff, und 26, 2019.



Spartalizumab plus dabrafenib and trametinib in patients with previously untreated *BRAF* V600–mutant unresectable or metastatic melanoma: results from the randomized part 3 of the Phase III COMBI-i trial

 Paul D. Nathan¹ Reinhard Dummer,² Georgina V. Long³ Paolo A. Ascierto,⁴

 Hussein A. Tawbi⁵ Caroline Robert,⁶ Piotr Rutkowski,⁷ Oleg Leonov,⁸ Caroline

 Dutriaux,⁹ Mario Mandala,¹⁰ Paul Lorigan,¹¹ Pier Francesco Ferrucci,¹² Keith T.


 Flaherty,¹³ Jan C. Brase,⁴¹ Steven Green,¹⁵ Tomas Haas,¹⁴ Alsha Masood,¹⁶ Eduard

 Gasal,¹⁶ Anton Ribas,¹⁷ Dirk Schadendor¹⁶

Oppertune of Media Douclog, Noor Homos Caroc Costes, Northwess, OK: Oppertune of Domassiog, Usiversy Inspecta Zeich Kin-Cherror Come, Zinki, Xinki Kunturu, Oppertune of Media Oncologi, Malanou statish Australa, Na Usiversy I of Jongs, and Boyl Meth-Roman Methods, Caro Markan, Caro Marten of Method Oncologi, Malanou statish Australa, Na Usiversy I of Jongs, and Boyl Meth-Roman Methods, Caro Markan, San Kana, San Kana,




COMBI-i Study Design (Part 3)




Primary endpoint: Investigator-assessed PFS using RECIST 1.1 Secondary endpoints: OS, ORR, DOR, DCR, safety, PRO, PK

BID, twice daily; DCR, disease control rate; DOR, duration of response; ECOG PS, Eastern Cooperative Oncology Group performance status; LDH, lactate dehydrogenase; ORR, objective response rate; OS, overall survival; PFS, progression-free survival; PK, pharmacokinetics; Q4W, every 4 weeks; QD, once daily; RECIST, Response Evaluation Critleria in Solid Tumors.

Investigator-Assessed Progression-Free Survival






Overall survival could be statistically tested only after the primary endpoint was determined to be statistically significant



- Immunotherapy
- Targeted therapy
- Choosing between immunotherapy & targeted therapy as first-line
- Combining immunotherapy with targeted therapy
- Future directions


The Moving Overall Survival Bar for Metastatic Melanoma

Pre-Checkpoint Blockade/ BRAF-Targeted Therapy: Chemotherapy



The Moving Overall Survival Bar for Metastatic Melanoma

Pre-Checkpoint Blockade/ BRAF-Targeted Therapy: Chemotherapy



ANNUAL MEETING

Allison Betof Warner, MD, PhD

@DrBetofM0Ph0


authic: Inseland by ASUS. Parmission required for muse

CHOWLEDGE COMONNE CANCER


5

The Moving Overall Survival Bar for Metastatic Melanoma

Pre-Checkpoint Blockade/ BRAF-Targeted Therapy: Chemotherapy



PD-1 +/- CTLA-4 Inhibition







Content of this presentation is the property of the author, licensed by ASCO. Permission required for reuse.

(Still) Unmet Clinical Need for Advanced Melanoma


Pre-Checkpoint Blockade/ BRAF-Targeted Therapy: Chemotherapy



PD-1 +/- CTLA-4 Inhibition




Clinical Potential of Adoptive Cell Therapy




Stabaar-MW, st at Orchman Arch 2010 474 448.

방법 사람이 많은 것이 같아요. 것은 것이 같아요.

Patient Journey and TIL Manufacturing



Lifileucel for PD-1 Refractory Melanoma




6.7

Select Accruing Melanoma TIL Trials (*Beyond Phase 1)

Trial Identifier	Sponsor	Description
NCT05398640		Expanded access program for lifileucel
NCT02278887	Netherlands Cancer Institute	Phase 3, Lymphodepletion+ TIL+ IL-2 vs. ipilimumab
NCT03645928		Phase 2, Lymphodepletion+ lifileucel + IL-2
NCT05050006		Phase 2, Lymphodepletion+ ITIL-168 + IL-2
NCT03467516	UPMC Hillman Cancer Center	Phase 2, Lymphodepletion+ TIL + IL-2
NCT04762225	Repertoire Immune Medicines	Phase 1/2, Autologous Multi-Targeted T Cell Therapy (RPTR-168)
NCT03997474		Phase 1/2, Lymphodepletion +ATL001 +/- checkpoint inhibitor+ IL-2
NCT03815682		Phase 1/2, Autologous Multi-Targeted T Cell Therapy + IL-15 (RPTR-147:1) +/- Pembro
NCT03638375		Phase 1/2, TIL + nivo +/- IFN-α
NCT03374839	Nantes University Hospital	Phase 1/2, TIL + IL-2 +/- DC vaccine

Rationale for RELA + NIVO

- LAG-3 and PD-1 are distinct immune checkpoints, often co-expressed on tumor-infiltrating lymphocytes, and contribute to tumor-mediated T-cell exhaustion^{1,2}
- In preclinical models, LAG-3 and PD-1 blockade demonstrated synergistic antitumor activity¹
- RELA + NIVO demonstrated clinically meaningful antitumor activity including durable objective responses and was well tolerated in patients with melanoma that was relapsed/refractory to anti-PD-1 therapy^{3,4}



APC, antigen presenting cell; MHC, major histocompatibility complex; TCR, T-cell receptor. 1. Woo S-R, et al. Concer Res 2012;72:917-927; 2. Anderson AC, et al. Immunity 2016;44:989-1004; 3. Ascierto PA, et al. Oral presentation at ASCO Annual Meeting; June 2-6, 2017; Chicago, IL. Abstract 9520; 4. Ascierto PA, et al. Oral presentation at ESMO Congress; September 8-12, 2017; Madrid, Spain. Abstract LBA18.

Study design


RELATIVITY-047 is a global, randomized, double-blind, phase 2/3 study

Key eligibility criteria

- Previously untreated unresectable or metastatic melanoma^a
- ECOG PS 0-1


Stratification factors

- LAG-3^b
- · PD-L1c
- · BRAF
- AJCC v8 M stage



AJCC, American Joint Committee on Cancer; BICR, blinded independent central review; CTLA-4, cytotoxic T lymphocyte antigen-4; BCCD PS, Eastern Cooperative Oncology Group performance status; BHC, Immunchistochemistry; IV, Intravenous; ORR, overall response rate; Q4W, every 4 weeks; R, randomication. ClinicalTrials.grv: NCT0940902; Upton E, et al. Porter presentation at ESMC Congress; October 19-23, 3018; Munich, Germany, Abstract 1902TIP. Prior adjunant/neoadjunant treatment permitted (anti-PD-1) or anti-CTLA-4 permitted of at least 6 months between the last dose and recurrence; Interferon therapy permitted if the last dose was at least 6 weeks before randomization; MAG-3 expression on literum cells was determined using an analytically validated IHC assay (LabCorp); PD-L1 expression on tumor cells was determined using the validated Agilent/Dako PD-L1 IHC 28-8 pharm0x best; "Pirst tumor assessment (RECIST v1.1) performed 12 weeks after randomization, every 8 weeks up to 52 weeks, and then every 12 weeks. Database lock-date. Barch 9, 2021.

PFS, OS, and ORR in all randomized patients



DBL date: October 28, 2021. Median follow-up; 19.3 mo


Internical analytics (8) and A-alase: meeting Caspingertood kased and waithed by each seat. Stratified by UAC-5, MAP instances mana, and UAC-6 mags. PD-11 was removed from the Mitorian backase (1) told to adapted with each seat. Stratified by UAC-5, MAP instances mana, and UAC-6 mags. PD-11 was removed from the Mitorian backase (1) told to adapted with each seat. Stratified by UAC-5, MAP instances mana, and UAC-6 mags. PD-11 was removed from the Mitorian backase (1) told to adapted with each seat. Stratified by UAC-5, MAP instances mana, and UAC-6 mags. PD-11 was removed from the Mitorian potential backase (1) told to adapted with each seat. Stratified by UAC-5, MAP instances mana, and UAC-6 mags. PD-11 was removed from backase (1) told to adapted with each seat. Stratified by UAC-5, MAP instances mana, and UAC-6 mags. PD-11 was removed from backase (1) told to adapted with each seat. Stratified by UAC-5, MAP instances mana, and UAC-6 mags. PD-11 was removed from backase (1) told to adapted with each seat. Stratified by UAC-5, MAP instances mana, and UAC-6 mags. PD-11 was removed from backase (1) told to adapted with each seat. Stratified by UAC-5, MAP instances mana, and UAC-6 mags. PD-11 was removed from backase (1) told to adapted with each seat. Stratified by UAC-5, MAP instances management, isotarian each seat. Stratified by UAC-5, MAP instances management, isotarian each seat. Stratified by UAC-5, MAP instances management, isotarian each seat. Stratified by UAC-5, MAP instances management, isotarian each seat. Stratified by UAC-5, MAP instances management, isotarian each seat. Stratified by UAC-5, MAP instances management, isotarian each seat. Stratified by UAC-5, MAP instances management, isotarian each seat. Stratified by UAC-5, MAP instances management, isotarian each seat. Stratified by UAC-5, MAP instances management, isotarian each seat. Stratified by UAC-5, MAP instances management, isotarian each seat. Stratified by UAC-5, MAP instances management, isotarian each seat. Stratified by UAC-5, MAP ins

Jung GV, et al. Oral presentation at the American Society of Divisiol Decisiog/ USCOL 2022 Maryh Plenary Series; March 15, 2022; Virtual: AbArset: MARRE.

6


Why neoadjuvant treatment?

- Downstaging disease
- → facilitate resection/less morbidity
- Destruction of micrometastases
- → prevention of distant metastasis
- More tumor antigens
- → better and deeper immune response
- Objectify the individual therapy response
- → Personalised therapy



S1801 Study Schema

Primary endpoint: Event-free survival



SWOG CANCER RESEARCH RESEARCH NCI National Clinical Trials Network


I radiographic assessment
(scans)



Surgery type and extent was required to be pre-specified and carried out regardless of radiologic response to therapy




S1801 primary endpoint: Event-free survival





Overall survival






Summary & Conclusions

- Immunotherapy is an option for all patients
 - Single agent PD1
 - Combination PD-1/CTLA-4
- Targeted therapy (BRAF/MEK combination) is an option for BRAF-MT patients
- Triple therapy for BRAF-MT patients is an approved option but the data are controversial
- For first-line treatment, combination immunotherapy (CTLA-4 + PD1) is preferred for most patients including those with a BRAF mutation
- Future directions include new targets and other immunotherapy approaches including neoadjuvant therapy

How I Treat Metastatic Melanoma



Thank you!